Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics

Eton Pharmaceuticals, Inc. (ETON): $5.14

-0.36 (-6.55%)

POWR Rating

Component Grades














  • ETON scores best on the Growth dimension, with a Growth rank ahead of 92.61% of US stocks.
  • ETON's strongest trending metric is Stability; it's been moving up over the last 31 weeks.
  • ETON ranks lowest in Momentum; there it ranks in the 5th percentile.

ETON Stock Summary

  • Eton Pharmaceuticals Inc's stock had its IPO on November 13, 2018, making it an older stock than merely 6.17% of US equities in our set.
  • With a year-over-year growth in debt of 56.63%, Eton Pharmaceuticals Inc's debt growth rate surpasses 86.8% of about US stocks.
  • As for revenue growth, note that ETON's revenue has grown 2,290.14% over the past 12 months; that beats the revenue growth of 99.44% of US companies in our set.
  • Stocks that are quantitatively similar to ETON, based on their financial statements, market capitalization, and price volatility, are GSMG, TBIO, MOMO, INFU, and STMP.
  • ETON's SEC filings can be seen here. And to visit Eton Pharmaceuticals Inc's official web site, go to

ETON Valuation Summary

  • ETON's price/earnings ratio is -9.9; this is 129.12% lower than that of the median Healthcare stock.
  • ETON's EV/EBIT ratio has moved down 0 over the prior 33 months.
  • Over the past 33 months, ETON's price/earnings ratio has gone down 2.3.

Below are key valuation metrics over time for ETON.

Stock Date P/S P/B P/E EV/EBIT
ETON 2021-06-15 12.6 7.8 -12.1 -10.9
ETON 2020-11-18 428.5 128.7 -7.8 -8.0
ETON 2020-02-14 249.6 10.1 -3.0 -5.8
ETON 2019-06-05 NA 7.4 -3.8 -9.6
ETON 2019-04-16 NA 5.0 -3.5 -8.2
ETON 2019-02-28 NA -8.5 -10.1 -12.0

ETON Price Target

For more insight on analysts targets of ETON, see our ETON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.50 Average Broker Recommendation 1.5 (Moderate Buy)

ETON Stock Price Chart Interactive Chart >

Price chart for ETON

ETON Price/Volume Stats

Current price $5.14 52-week high $10.30
Prev. close $5.50 52-week low $5.12
Day low $5.12 Volume 234,600
Day high $5.58 Avg. volume 376,743
50-day MA $6.27 Dividend yield N/A
200-day MA $7.68 Market Cap 125.97M

Eton Pharmaceuticals, Inc. (ETON) Company Bio

Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.

ETON Latest News Stream

Event/Time News Detail
Loading, please wait...

ETON Latest Social Stream

Loading social stream, please wait...

View Full ETON Social Stream

Latest ETON News From Around the Web

Below are the latest news stories about Eton Pharmaceuticals Inc that investors may wish to consider to help them evaluate ETON as an investment opportunity.

What You Need To Know About Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Investor Composition

A look at the shareholders of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) can tell us which group is most powerful...

Yahoo | July 14, 2021

Where Do Hedge Funds Stand On Eton Pharmaceuticals, Inc. (ETON)?

A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

Yahoo | June 28, 2021

Eton Pharmaceuticals Buys US, Canadian Rights To Zeneo Hydrocortisone Autoinjector

Eton Pharmaceuticals Inc (NASDAQ: ETON) has acquired the U.S. and Canadian rights to Crossject's Zeneo hydrocortisone needleless autoinjector. The product is under development as a rescue treatment for adrenal crisis. Zeneo is a pre-filled, single-use device that propels medication through the skin in less than a tenth of a second. Crossject holds more than 400 global patents on the device, including 24 issued in the U.S. extending as far as 2037. Eton expects to submit a marketing application f

Yahoo | June 16, 2021

Eton Pharmaceuticals Acquires U.S. and Canadian Rights to ZENEO® Hydrocortisone Autoinjector

Expands Eton’s Adrenal Insufficiency Orphan Drug PortfolioZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency HydrocortisoneProprietary ZENEO® Needleless Device is Covered by 24 U.S. Patents Extending as Far as 2037 DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced

Yahoo | June 15, 2021

Eton Pharmaceuticals Announces FDA Approval of Rezipres® (Ephedrine Hydrochloride Injection)

DEER PARK, Ill., June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia. “We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelli

Yahoo | June 15, 2021

Read More 'ETON' Stories Here

ETON Price Returns

1-mo -14.48%
3-mo -40.30%
6-mo -42.89%
1-year -23.05%
3-year N/A
5-year N/A
YTD -36.78%
2020 12.92%
2019 17.65%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7618 seconds.